Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-13T07:23:06.638Z Has data issue: false hasContentIssue false

Real World Effectiveness of rTMS in Depression and Anxiety

Published online by Cambridge University Press:  01 August 2024

Milind Thanki*
Affiliation:
Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, United Kingdom
Paul Briley
Affiliation:
Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, United Kingdom
Sarah Ottahal
Affiliation:
Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, United Kingdom Sheffield Hallam University, Sheffield, United Kingdom
Sudheer Lankappa
Affiliation:
Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, United Kingdom
Mohammad Zia Ul Haq Katshu
Affiliation:
Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, United Kingdom Institute of Mental Health, University of Nottingham, Nottingham, United Kingdom
*
*Presenting author.
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Aims

Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation recommended by NICE for treatment of depression with minimal side-effects and a high patient acceptability. Our aim was to assess the effectiveness of rTMS in real world clinical service in alleviating symptoms of depression and anxiety.

Methods

All patients receiving rTMS in our Centre for Neuromodulation Services (CNS) received 5 daily treatment sessions a week for a period of 5 weeks (25 sessions in total). All patients routinely completed PHQ-9, BDI-II and GAD-7 measures before and after the course of treatment. The scores on these measures were retrospectively analysed using paired-sample t-test.

Results

All 15 patients completed the PHQ-9 and GAD-7 scales while 10 patients completed BDI-II. Eleven patients (73%) had improved PHQ-9 scores post-treatment with average improvement of 5.5 points which was statistically significant [paired-sample t-test: t(14) = 3.019, p = 0.009]. Nine patients (90%) had improved BDI-II scores post-treatment with average reduction of 36% from baseline which was statistically significant [t(9) = 3.681, p = 0.005]. Eleven patients (73%) had improved GAD-7 scores post-treatment, with average reduction of 4 points. This reduction was also statistically significant [t(14) = 3.038, p = 0.009]. Improvement in all measures was also of a level that would be considered clinically significant for these measures. All patients tolerated the treatment well with no patients dropping out due to side effects.

Conclusion

With the limitation of relatively small sample size, our initial analysis indicates that rTMS treatment offered in real world clinical service is effective in treating symptoms of depression. Although our protocol was not intended to treat anxiety, our patients had remarkable improvement in anxiety symptoms as well.

Type
1 Research
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Footnotes

Abstracts were reviewed by the RCPsych Academic Faculty rather than by the standard BJPsych Open peer review process and should not be quoted as peer-reviewed by BJPsych Open in any subsequent publication.

Submit a response

eLetters

No eLetters have been published for this article.